Zynex (NASDAQ:ZYXI) Stock Rating Reaffirmed by HC Wainwright

Zynex (NASDAQ:ZYXIGet Rating)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Friday, PriceTargets.com reports.

Zynex Stock Up 10.0 %

NASDAQ ZYXI opened at $8.58 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.07 and a current ratio of 3.67. The company has a market capitalization of $335.05 million, a P/E ratio of 17.51 and a beta of 0.81. Zynex has a one year low of $4.97 and a one year high of $14.24. The stock has a 50 day moving average price of $7.67 and a 200-day moving average price of $7.07.

Zynex (NASDAQ:ZYXIGet Rating) last posted its earnings results on Thursday, April 28th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The firm had revenue of $31.08 million for the quarter, compared to the consensus estimate of $30.88 million. Zynex had a net margin of 13.98% and a return on equity of 28.38%. As a group, equities analysts predict that Zynex will post 0.43 EPS for the current fiscal year.

Institutional Trading of Zynex

A number of institutional investors have recently bought and sold shares of ZYXI. Allspring Global Investments Holdings LLC bought a new stake in Zynex in the fourth quarter worth $555,000. Yousif Capital Management LLC bought a new stake in Zynex in the fourth quarter worth $220,000. Qube Research & Technologies Ltd bought a new stake in Zynex in the fourth quarter worth $221,000. Nisa Investment Advisors LLC purchased a new stake in Zynex in the fourth quarter worth $63,000. Finally, Northern Trust Corp increased its stake in Zynex by 0.7% in the fourth quarter. Northern Trust Corp now owns 227,778 shares of the company’s stock worth $2,271,000 after purchasing an additional 1,608 shares during the period. 28.06% of the stock is currently owned by institutional investors.

Zynex Company Profile

(Get Rating)

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.

Recommended Stories

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.